Mealey's (April 13, 2023, 1:36 PM EDT) -- SEATTLE — A federal judge in Washington dismissed shareholder claims with prejudice in a class action alleging that a clinical-stage biopharmaceutical company and certain of its officers and directors misrepresented the safety and efficacy of the company’s developmental drug for use as an anti-tumor drug, ruling that the shareholders failed to cure pleading deficiencies that led to a prior dismissal of their federal securities law claims....